Since then, another anti-CD38 monoclonal antibody (humanized IgG1), isatuximab (Sarclisa®), which binds a distinct epitope and has shown to mediate MM cell death via ADCC, ADCP, CDC and the direct induction of caspase-dependent apoptosis without the need for a cross-linking antibody [11,12], was approved by the FDA in 2020, in combination with pomalidomide and dexamethasone, as a therapy for MM patients who have had at least two prior therapies [11,12]. Here, CD38 is linked to Miyoshi myopathy.